Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus

• Published in: Journal of the American College of Cardiology Vol. 81; no. 25; pp. 2391 - 2402
• Main Authors: Berg, David D., Moura, Filipe A., Bellavia, Andrea, Scirica, Benjamin M., Wiviott, Stephen D., Bhatt, Deepak L., Raz, Itamar, Bohula, Erin A., Giugliano, Robert P., Park, Jeong-Gun, Feinberg, Mark W., Braunwald, Eugene, Morrow, David A., Sabatine, Marc S.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 27.06.2023
• Subjects: atherothrombosis; Cardiovascular; clinical trials; diabetes mellitus; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - epidemiology; Humans; ischemic stroke; myocardial infarction; Myocardial Infarction - complications; Proprotein Convertase 9; Risk Assessment; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; ARR; T2DM; ASCVD; myocardial infarction; atherothrombosis; clinical trials; diabetes mellitus; MI; SGLT2i; ischemic stroke; HF; heart failure; absolute risk reduction; atherosclerotic cardiovascular disease; type 2 diabetes mellitus; sodium-glucose cotransporter-2 inhibitor
• ISSN: 0735-1097; 1558-3597; 1558-3597
• DOI: 10.1016/j.jacc.2023.04.031

Risk of atherothrombotic events is not uniform in patients with type 2 diabetes mellitus (T2DM). Tailored risk assessment may help guide selection of pharmacotherapies for cardiovascular primary and secondary prevention. The purpose of this study was to develop a risk model for atherothrombosis in p...